Overcoming acquired resistance to tumor necrosis factor-related apoptosis-inducing ligand by Bcl-XL small interfering RNA in human colon cancer / 中华肿瘤杂志
Chinese Journal of Oncology
;
(12): 245-249, 2008.
Artículo
en Chino
| WPRIM
| ID: wpr-348121
ABSTRACT
<p><b>OBJECTIVE</b>To investigate the reversing effect of Bcl-XL small interfering RNA (siRNA) on the acquired resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in human colon cancer.</p><p><b>METHODS</b>Human colon cancer cells DLD1-TRAIL/R, with acquired resistance to TRAIL, were firstly transfected with Bcl-XL siRNA for 24 h followed by the treatment of TRAIL protein. The survival rate of DLD1-TRAIL/R cells was assessed by FACS analysis and cell number counting, respectively, and activation of its apoptotic signaling was evaluated by Western blot.</p><p><b>RESULTS</b>Bcl-XL siRNA effectively downregulated the expression of Bcl-XL protein and reversed the acquired resistance to TRAIL in DLD1-TRAIL/R cells. After combination treatment of Bcl-XL siRNA and TRAIL protein, the apoptotic rate of DLD1-TRAIL/R cells was more than 50% and survival rate was less than 40%, whereas there was no effect on the survival of DLD1-TRAIL/R cells after treatment with control treatment or TRAIL protein treatment alone (P < 0.05). Western blot analysis demonstrated that caspase-8, caspase-9, Bid, caspase-3, and poly (ADP-ribose) polymerase (PARP) were obviously activated after combination treatment with Bcl-XL siRNA and TRAIL protein, and the release of cytochrome C was also significantly increased.</p><p><b>CONCLUSION</b>Bcl-XL siRNA can effectively reverse the acquired resistance to TRAIL in human colon cancer cells, suggesting that it might be a new strategy for overcoming the resistance in cancer therapy.</p>
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Patología
/
Transfección
/
Supervivencia Celular
/
Poli(ADP-Ribosa) Polimerasas
/
Apoptosis
/
Neoplasias del Colon
/
Resistencia a Antineoplásicos
/
Caspasas
/
ARN Interferente Pequeño
/
Línea Celular Tumoral
Límite:
Humanos
Idioma:
Chino
Revista:
Chinese Journal of Oncology
Año:
2008
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS